The Generic and Biosimilar Medicines Association (GBMA) is pleased to announce the completion of its Code of Practice review for 2016. The review indicates that the Code has been effective in formalising the high standards of conduct adhered to by its Members.
Pursuant to section 14 of the Code, the Association prepared its annual report for the GBMA Board. This report is posted below:
